This Preclinical Biotech Is Going Clinical This Year – And Goldman Says It’s A Buy
Today’s article highlights a biotech firm that, after being relatively quiet for several years, the market may begin to take notice of as it goes…
Today’s article highlights a biotech firm that, after being relatively quiet for several years, the market may begin to take notice of as it goes…
On the heels of Novavax receiving $1.6 billion in federal aid for its COVID-19 vaccine candidate, the author of today’s article advises that “investors might…
“With the scramble for viral and antibody testing kits, and the ultimate goal of finding a vaccine for Covid-19, many biotech companies are suddenly in…
If you need any further evidence of just how much the COVID-19 pandemic has increased the allure of biotechnology stocks, consider the little-known Chinese biotech…